SARS-CoV-2 Impairs Dendritic Cells and Regulates DC-Sign Gene Expression in Tissues

The current spreading coronavirus SARS-CoV-2 is highly infectious and pathogenic. In this study, we screened the gene expression of three host receptors (ACE2, DC-SIGN and L-SIGN) of SARS coronaviruses and dendritic cells (DCs) status in bulk and single cell transcriptomic datasets of upper airway, lung or blood of COVID-19 patients and healthy controls. In COVID-19 patients, DC-SIGN gene expression was interestingly decreased in lung DCs but increased in blood DCs. Within DCs, conventional DCs (cDCs) were depleted while plasmacytoid DCs (pDCs) were augmented in the lungs of mild COVID-19. In severe cases, we identified augmented types of immature DCs (CD22+ or ANXA1+ DCs) with MHCII downregulation. In this study, our observation indicates that DCs in severe cases stimulate innate immune responses but fail to specifically present SARS-CoV-2. It provides insights into the profound modulation of DC function in severe COVID-19

New insights into the design for end-of-life variability of NBTI in scaled high-κ/metal-gate Technology for the nano-reliability era

In this paper, a new methodology for the assessment of end-of-life variability of NBTI is proposed for the first time. By introducing the concept of characteristic failure probability, the uncertainty in the predicted 10-year VDD is addressed. Based on this, variability resulted from NBTI degradation at end of life under specific VDD is extensively studied with a novel characterization technique. With the further circuit level analysis based on this new methodology, the timing margin can be relaxed. The new methodology has also been extended to FinFET in this work. The wide applicability of this methodology is helpful to future reliability/variability-aware circuit design in nano-CMOS technology. ? 2014 IEEE.EIFebruary34.1.1-34.1.42015-Februar

The percentage of early-stage colorectal cancer detection in risk factor (RF) and RF-fecal immunochemical test (FIT) strategies.

The percentage of early-stage colorectal cancer detection in risk factor (RF) and RF-fecal immunochemical test (FIT) strategies.</p

Screening yield of colonoscopy screening in risk factor (RF) and RF–fecal immunochemical test (FIT) strategies.

Screening yield of colonoscopy screening in risk factor (RF) and RF–fecal immunochemical test (FIT) strategies.</p

Cost analysis from a government perspective in risk factor (RF) and RF–fecal immunochemical test (FIT) strategies.

Cost analysis from a government perspective in risk factor (RF) and RF–fecal immunochemical test (FIT) strategies.</p

Characteristics of high colorectal cancer risk participants identified using the risk factor (RF) or RF–fecal immunochemical test (FIT) strategies.

Characteristics of high colorectal cancer risk participants identified using the risk factor (RF) or RF–fecal immunochemical test (FIT) strategies.</p